These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Increased thyroid-stimulating hormone levels associated with concomitant administration of levothyroxine and raloxifene. Garwood CL; Van Schepen KA; McDonough RP; Sullivan AL Pharmacotherapy; 2006 Jun; 26(6):881-5. PubMed ID: 16716142 [TBL] [Abstract][Full Text] [Related]
3. [Hypothyroidism due to pseudo-malabsorption of levothyroxine--Case 12/2009]. Müssig K; Mörike K; Klein R; Sträter J; Georges G; Häring HU; Schnauder G Dtsch Med Wochenschr; 2009 Dec; 134(49):2514. PubMed ID: 19941234 [TBL] [Abstract][Full Text] [Related]
4. Effects of evening vs morning thyroxine ingestion on serum thyroid hormone profiles in hypothyroid patients. Bolk N; Visser TJ; Kalsbeek A; van Domburg RT; Berghout A Clin Endocrinol (Oxf); 2007 Jan; 66(1):43-8. PubMed ID: 17201800 [TBL] [Abstract][Full Text] [Related]
5. Noncompliance with medical treatment: pseudomalabsorption of levothyroxine. Eledrisi MS; Szymajda A; Alshanti M; Urban RJ South Med J; 2001 Aug; 94(8):833-6. PubMed ID: 11549198 [TBL] [Abstract][Full Text] [Related]
6. Chronic intestinal giardiasis with isolated levothyroxine malabsorption as reason for severe hypothyroidism--implications for localization of thyroid hormone absorption in the gut. Seppel T; Rose F; Schlaghecke R Exp Clin Endocrinol Diabetes; 1996; 104(2):180-2. PubMed ID: 8740944 [TBL] [Abstract][Full Text] [Related]
7. New medications which decrease levothyroxine absorption. John-Kalarickal J; Pearlman G; Carlson HE Thyroid; 2007 Aug; 17(8):763-5. PubMed ID: 17725434 [TBL] [Abstract][Full Text] [Related]
8. Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders. Csako G; McGriff NJ; Rotman-Pikielny P; Sarlis NJ; Pucino F Ann Pharmacother; 2001 Dec; 35(12):1578-83. PubMed ID: 11793625 [TBL] [Abstract][Full Text] [Related]
9. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Gol M; Akan P; Dogan E; Karas C; Saygili U; Posaci C Maturitas; 2006 Feb; 53(3):252-9. PubMed ID: 15990257 [TBL] [Abstract][Full Text] [Related]
11. Effects of two novel selective estrogen receptor modulators, raloxifene, tamoxifen, and ethinyl estradiol on the uterus, vagina and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis). Sikoski P; Register TC; Lees CJ; Lundeen S; Hutchison J; Brown KH; Cline JM Am J Obstet Gynecol; 2007 Jan; 196(1):75.e1-7. PubMed ID: 17240242 [TBL] [Abstract][Full Text] [Related]
12. Effects of raloxifene hydrochloride on endometrial cancer cells in vitro. Hibner M; Magrina JF; Lefler SR; Cornella JL; Pizarro AR; Loftus JC Gynecol Oncol; 2004 Jun; 93(3):642-6. PubMed ID: 15196858 [TBL] [Abstract][Full Text] [Related]
13. Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide. Sperber AD; Liel Y Arch Intern Med; 1992 Jan; 152(1):183-4. PubMed ID: 1728914 [TBL] [Abstract][Full Text] [Related]
14. Effects of raloxifene on changes in bone density. Miskić B; Bistrović D; Vizner B; Cosić V; Miskić D; Herman D Coll Antropol; 2006 Dec; 30(4):767-70. PubMed ID: 17243547 [TBL] [Abstract][Full Text] [Related]
15. A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women. Baytur YB; Ozbilgin K; Cilaker S; Lacin S; Kurtul O; Oruc S; Koyuncu FM Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):94-103. PubMed ID: 16973256 [TBL] [Abstract][Full Text] [Related]
16. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene. Christodoulakos G; Lambrinoudaki I; Panoulis C; Sioulas V; Rizos D; Caramalis G; Botsis D; Creatsas G Maturitas; 2005 Apr; 50(4):321-30. PubMed ID: 15780533 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of combined levothyroxine and liothyronine as compared with levothyroxine monotherapy in primary hypothyroidism: a randomized controlled trial. Valizadeh M; Seyyed-Majidi MR; Hajibeigloo H; Momtazi S; Musavinasab N; Hayatbakhsh MR Endocr Res; 2009; 34(3):80-9. PubMed ID: 19701833 [TBL] [Abstract][Full Text] [Related]
18. Effects of tamoxifen and raloxifene on normal human endometrial cells in an organotypic in vitro model. Bläuer M; Heinonen PK; Rovio P; Ylikomi T Eur J Pharmacol; 2008 Sep; 592(1-3):13-8. PubMed ID: 18638473 [TBL] [Abstract][Full Text] [Related]
19. [A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women]. Zheng SR; Wu YY; Zhang ZL; Yang X; Hui Y; Zhang Y; Chen SL; Den WH; Liu H; Ekangaki A; Stocks J; Harper K; Liu JL Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):226-9. PubMed ID: 12885371 [TBL] [Abstract][Full Text] [Related]
20. Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study. Di Girolamo G; Keller GA; de Los Santos AR; Schere D; Gonzalez CD Clin Ther; 2008 Nov; 30(11):2015-23. PubMed ID: 19108789 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]